Skip to main content
SpringerLink
Log in

Non-absorbable disaccharides and antibacterials are the treatment of choice for hepatic encephalopathy

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Phongsamran PV, Kim JW, Cupo J, et al. Pharmacotherapy for hepatic encephalopathy. Drugs 2010; 70(9): 1131–48

    Article  PubMed  CAS  Google Scholar 

  2. Butterworth RF. Thiamine deficiency-related brain dysfunction in chronic liver failure. Metab Brain Dis 2009 Mar; 24(1): 189–96

    Article  PubMed  CAS  Google Scholar 

  3. Dhiman RK, Sawhney MS, Chawla YK, et al. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000; 45(8): 1549–52

    Article  PubMed  CAS  Google Scholar 

  4. Horsmans Y, Solbreux PM, Daenens C, et al. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther 1997; 11(1): 165–70

    Article  PubMed  CAS  Google Scholar 

  5. Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45(3): 549–59

    Article  PubMed  Google Scholar 

  6. Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lactitol and lactulose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987; 7(4): 639–43

    Article  PubMed  CAS  Google Scholar 

  7. Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997; 26(6): 1410–4

    Article  PubMed  CAS  Google Scholar 

  8. Heredia D, Terés J, Orteu N, et al. Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy. J Hepatol 1988; 7(1): 106–10

    Article  PubMed  CAS  Google Scholar 

  9. Lanthier PL, Morgan MY. Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose. Gut 1985; 26(4): 415–20

    Article  PubMed  CAS  Google Scholar 

  10. Morgan MY, Hawley KE. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 1987; 7(6): 1278–84

    Article  PubMed  CAS  Google Scholar 

  11. Morgan MY, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients: a randomized, cross-over study. J Hepatol 1989; 8(2): 208–17

    Article  PubMed  CAS  Google Scholar 

  12. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial. Am J Dig Dis 1978; 23(5): 398–406

    Article  PubMed  CAS  Google Scholar 

  13. Conn HO, Leavy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portalsystemic encephalopathy: a double-blind controlled trial. Gastroenterology 1977; 72 (4 Pt 1): 573–83

    PubMed  CAS  Google Scholar 

  14. Orlandi F, Freddara U, Candelaresi MT, et al. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 1981; 26(6): 498–506

    Article  PubMed  CAS  Google Scholar 

  15. Strauss E, Tramote R, Silva EP, et al. Double-blind, randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992; 39(6): 542–5

    PubMed  CAS  Google Scholar 

  16. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13(2): 109–18

    Article  PubMed  CAS  Google Scholar 

  17. Fera G, Agostinacchio F, Nigro M, et al. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993; 4(1): 57–66

    Google Scholar 

  18. Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res 1993; 54(5): 598–609

    Article  Google Scholar 

  19. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007; 52(2): 737–41

    Article  PubMed  CAS  Google Scholar 

  20. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003; 38(1): 51–8

    Article  PubMed  CAS  Google Scholar 

  21. Massa P, Vallerino E, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double-blind, double-dummy study versus lactulose. J Clin Res 1993; 4(1): 7–18

    Google Scholar 

  22. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005; 46(3): 399–407

    Article  PubMed  CAS  Google Scholar 

  23. Miglio F, Valpiani D, Rossellini SR, et al. Rifaximin, a nonabsorbable rifamycin, for the treatment of hepatic encephalopathy: a double-blind, randomized trial. Curr Med Res Opin 1997; 13(10): 593–601

    Article  PubMed  CAS  Google Scholar 

  24. Pedretti G, Calzetti C, Missale G, et al. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial. Ital J Gastroenterol 1991; 23(4): 175–8

    PubMed  CAS  Google Scholar 

  25. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systemic review of randomized clinical trials. BMJ 2004; 328(7447): 1046–51

    Article  PubMed  CAS  Google Scholar 

  26. Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. Gut 1982; 23(1): 1–7

    Article  PubMed  CAS  Google Scholar 

  27. Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 2005; 42(5): 674–9

    Article  PubMed  CAS  Google Scholar 

  28. Sharma BC, Sharma P, Agrawal A, et al. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009; 137(3): 885–91

    Article  PubMed  CAS  Google Scholar 

  29. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362(12): 1071–81

    Article  PubMed  CAS  Google Scholar 

  30. Gentile S, Guarino G, Romanov M, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005; 3(2): 184–91

    Article  PubMed  CAS  Google Scholar 

  31. Als-Nielsen B, Kjaergard Ll, Gluud C. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev 2004; (2): CD002798

  32. Naylor CD, O’Rouke K, Detsky As, et al. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy: a meta-analysis. Gastroenterology 1989; 97(4): 1033–42

    PubMed  CAS  Google Scholar 

  33. Als-Nielsen B, Koretz RL, Kjaergard LL, et al. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev 2003; (2): CD001939

  34. Malaguarnera M, Pistone G, Elvira R, et al. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 2005; 11(45): 7197–202

    PubMed  CAS  Google Scholar 

  35. del Olmo JA, Castillo M, Rodrigo JM, et al. Effects of L-carnitine upon ammonia tolerance test in cirrhotic patients. Adv Exp Med Biol 1990; 272: 197–208

    Article  PubMed  Google Scholar 

  36. Sharma P, Sharma BC, Puri V, et al. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008; 20(6): 506–11

    Article  PubMed  CAS  Google Scholar 

  37. Malaguarnera M, Greco F, Barone G, et al. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007; 52(11): 3259–65

    Article  PubMed  Google Scholar 

  38. Sushma S, Dasarathy S, Tandon RK, et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992; 16(1): 138–44

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Non-absorbable disaccharides and antibacterials are the treatment of choice for hepatic encephalopathy. Drugs Ther. Perspect 27, 17–21 (2011). https://doi.org/10.2165/11206630-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11206630-000000000-00000

Search

Navigation